- Home
- NRK vs RIGL Comparison
NRK vs RIGL Comparison
Compare NRK & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRK | RIGL |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 935.2M | 884.9M |
| IPO Year | 2002 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NRK | RIGL |
|---|---|---|
| Price | $9.97 | $45.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | ★ 296.7K | 217.9K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $35.79 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $9.73 | $24.84 |
| 52 Week High | $10.90 | $52.24 |
Technical Indicators
Market Signals| Indicator | NRK | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 37.66 | 59.92 |
| Support Level | $9.89 | $40.05 |
| Resistance Level | $10.67 | $49.50 |
| Average True Range (ATR) | 0.18 | 1.35 |
| MACD | -0.02 | -0.27 |
| Stochastic Oscillator | 18.28 | 43.86 |
Price Performance
Historical ComparisonAbout NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.